Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of ($0.36), $2.71 worse than the analyst estimate of $2.35. Revenue for the quarter came in at $329 million versus the consensus estimate of $486.84 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.